At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 30 enrolled
Drug / intervention
Cilostazol 50 mg Tablets +1 moredrug
Likely dose
Cilostazol 50 mg Tabletsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Relative Bioavailability Study of 50 mg Cilostazol Tablets Under Fasting Conditions
In Brief
A Phase 1 clinical trial evaluating Cilostazol 50 mg Tablets and Pletal® for Healthy. Completed, enrolled 30 participants across 2 sites.
Detailed Summary
This study will compare the relative bioavailability (rate and extent of absorption) of 50 mg Cilostazol Tablets manufactured by TEVA Pharmaceuticals Industries Ltd. and distributed by TEVA Pharmaceuticals USA with that of PLETAL Tablets manufactured by Otsuka Pharmaceuticals Co., Ltd. for Otsuka America Pharmaceutical, Inc. following a single oral dose (1 x 50 mg tablet) in healthy adult subjects administered under fasting conditions.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2004
Primary CompletionFeb 2004
First PostedFeb 2009
TodayJul 2026
First PostedFeb 10, 2009
Enrollment StartFeb 1, 2004
Primary CompletionFeb 1, 2004
TodayJul 2, 2026
Enrollment to primary: 0 daysPosted 17.4 years ago
Interventions
Cilostazol 50 mg Tabletsdrug
1 x 50 mg, single-dose fasting
Pletal®drug
1 x 50 mg, single-dose tablet